• Q3 FY25 revenue of $27.7 million, up 23.2% (+20.2% in constant currency) vs pcp
• Cash balance increased to $18.7 million as at 31 March 2025
• FY25 guidance reconfirmed: revenue ~$105 million, EBITDA $7-9 million, capex $3-4 million

SomnoMed Limited (ASX 'SOM' or the Company), the leading provider of oral appliance treatment solutions for sleep-related breathing disorders and obstructive sleep apnea (OSA), has reported its quarterly activities for the period ended 31 March 2025 (Q3 FY25). The Company achieved double-digit revenue growth across all geographies compared to the previous corresponding period (pcp). Q3 FY25 revenue was $27.7 million, up 23.2% (+20.2% in constant currency) versus the pcp. The Company's cash balance increased to $18.7 million as at 31 March 2025, with net cash of $17.7 million after drawing down $1.0 million in low-interest government-backed COVID-19 related unsecured loan facilities in Europe. SomnoMed has reconfirmed its FY25 guidance, including revenue of approximately $105 million, EBITDA of between $7 million to $9 million, and capex of between $3 million to $4 million. The Company also provided an update on the recent US tariffs, noting that it is working to leverage duty-free treatments for medical devices imported into the USA under the Nairobi Protocol.

FY25 guidance: revenue of approximately $105 million, EBITDA of between $7 million to $9 million, and capex of between $3 million to $4 million.